RxDoctor Payments Data

Michael Kowalczyk, DO

Internal Medicine · Lansing, MINPI 1649277211

Payments from drug & device makers

$7,513in general payments, 2019–2025

Across 429 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Novo Nordisk$923
  • Amgen$666
  • Johnson & Johnson$519
  • Pfizer$353
  • Merck$289
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$7,503100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,513 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$133,807
Medicare patients
551
Services billed
1,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$199,487
TrulicityDulaglutide129$197,726
JardianceEmpagliflozin126$148,074
OzempicSemaglutide65$84,693
XareltoRivaroxaban50$67,069
FarxigaDapagliflozin Propanediol49$54,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$53,395
JanuviaSitagliptin Phosphate27$45,827
MounjaroTirzepatide35$44,424
Tresiba Flextouch U-200Insulin Degludec21$36,056
OxycontinOxycodone Hcl25$33,484
MyrbetriqMirabegron30$30,366
RybelsusSemaglutide25$26,415
EntrestoSacubitril/Valsartan17$26,366
ProliaDenosumab15$25,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$139$242,150164 claims
PfizerEliquis$353$199,487193 claims
Boehringer IngelheimJardiance, Tradjenta$231$159,267138 claims
Novo NordiskOzempic, Rybelsus$923$111,10890 claims
GSKTrelegy Ellipta, Anoro Ellipta$276$70,18355 claims
Johnson & JohnsonXarelto$519$67,06950 claims
AstraZenecaFarxiga, Symbicort$225$60,02865 claims
MerckJanuvia$289$45,82727 claims
NovartisEntresto$272$26,36617 claims
AmgenProlia$666$25,60615 claims
AbbVieLinzess$944$12,32512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →